KOD
What one share of Kodiak Sciences holds
Biological Products, (No Diagnostic Substances)
Since its founding in 2009, Kodiak Sciences Inc. (“Kodiak,” the “Company,” “we” or “our”) has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.
Kodiak Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.18 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.76 |
| Cash and investments | $2.00 |
| Book value | $0.97 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.38 | $0.11 | −$2.33 | — | −$5.70 |
| 2017 | — | −$3.72 | $0.03 | −$2.38 | — | −$8.66 |
| 2018 | — | −$2.77 | $0.01 | −$1.94 | — | — |
| 2019 | — | −$1.25 | $0.01 | −$1.05 | — | $7.78 |
| 2020 | — | −$2.91 | $0.08 | −$1.91 | — | $16.84 |
| 2021 | — | −$5.16 | $0.33 | −$3.85 | — | $12.80 |
| 2022 | — | −$6.39 | $0.71 | −$4.66 | — | $8.33 |
| 2023 | — | −$4.97 | $0.79 | −$3.73 | — | $5.06 |
| 2024 | — | −$3.35 | $0.01 | −$2.24 | — | $2.85 |
| 2025 | — | −$4.32 | $0.01 | −$2.57 | — | $2.55 |